The startup manufactures non-invasive ear stimulation devices that utilize neuromodulation technology to reduce patient morbidities and healthcare costs. By minimizing complications and improving outcomes for fragile patients, the platform enables healthcare professionals to enhance patient care while lowering financial burdens.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients in the Intensive Care Unit (ICU) often experience complications driven by inflammation, leading to increased healthcare costs and extended hospital stays. Current methods for managing inflammation may be invasive or lack the precision needed to effectively mitigate these complications. The high cost of ICU care, driven by a relatively small percentage of patients consuming a large portion of resources, necessitates innovative approaches to improve patient outcomes and reduce financial burdens.
Solution
Aurenar develops a wearable neuromodulation device designed to reduce inflammation and improve outcomes for patients in the ICU. The ear-worn device non-invasively stimulates a nerve in the ear, boosting the body’s natural control of inflammation. By addressing the underlying cause of life-threatening and costly complications, Aurenar aims to significantly decrease hospital length of stay and lower the overall cost of care. Clinical pilot studies have demonstrated improved patient outcomes and reduced hospital length of stay using this approach.
Target Audience
The primary target audience includes healthcare professionals in intensive care units (ICUs) seeking to improve patient outcomes, reduce hospital stays, and lower healthcare costs associated with inflammation-related complications.
Features
- Non-invasive ear-worn device for neuromodulation.
- Targeted nerve stimulation to activate the body's natural anti-inflammatory response.
- Wearable form factor for continuous and convenient application.
- Demonstrated reduction in hospital length of stay in clinical pilot studies.
- Designed to minimize complications associated with inflammation in ICU patients.